Abstract
Impurities that are seen in the active pharmaceutical ingredients (API) and the degradants that are seen in the drug products are to be identified and quantified according to regulatory requirements, especially when they are recurring ones and above the threshold limits that are described in guidance documents such as the ones from International Conference on harmonization (ICH). The identification and quantification of these impurities become even more important, especially when they could potentially have safety related adverse implications such as genotoxicity. Impurities such as the genotoxic ones and/or others that are potentially unsafe need to be controlled to very low levels or to be eliminated, typically in the order of parts per millions (ppm). This is usually a very challenging endeavor to come up with analytical techniques that have detection systems and methodologies that are very sensitive to support very low levels of detection (LOD) and quantitation (LOQ). This article discusses the implications of such low level impurities in the API and DP and the associated analytical challenges in identifying and detecting these impurities.
Keywords
- Drug Product
- Active Pharmaceutical Ingredient
- Guidance Document
- Active Pharmaceutical Ingredient
- European Medicine Evaluation Agency
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReference
PhRMA Genetoxic Impurities-Task Force Publication”, PhRMA Task Force, Regulatory Toxicology and Pharmacology, 2006, 44: 198-211.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 American Association of Pharmaceutical Scientists
About this chapter
Cite this chapter
Mohan, G. (2010). Low Level Impurities in Drug Substances and Drug Products and the Analytical Challenges in Identification and Quantitation. In: Huynh-Ba, K. (eds) Pharmaceutical Stability Testing to Support Global Markets. Biotechnology: Pharmaceutical Aspects, vol XII. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-0889-6_16
Download citation
DOI: https://doi.org/10.1007/978-1-4419-0889-6_16
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-0888-9
Online ISBN: 978-1-4419-0889-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)